Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid

Leukemia

Volumn 13, Issue 11, 1999, Pages 1881-1892

  Andreeff, M ^a   Jiang, S ^a   Zhang, X ^a   Konopleva, M ^a   Estrov, Z ^a   Snell, V E ^a   Xie, Z ^a   Okcu, M F ^a   Sanchez Williams, G ^a   Dong, J ^a   Estey, E H ^a   Champlin, R C ^a   Kornblau, S M ^a   Reed, J C ^b   Zhao, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

AML; Apoptosis; BAD; Bcl 2; Bcl X(L); Minimal residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYTARABINE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL X; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0032721858     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401573     Document Type: Conference Paper

References (49)

1. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34:9-19.
2. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-5411.
3. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
4. Walton WI, Whysong D, O'Connor PM, Hockenberry D, Korsmyer SJ, Kohn KW. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 1993; 53: 151-157.
5. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
6. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994; 8: 1960-1969.
7. Kitada S, Takayama S, DeRiel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994; 4: 71-79.
8. Campos L, Sabido O, Rouault J-P, Guyotat D. Effects of Bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595-600.
9. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to Bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995; 55: 735-738.
10. Teixeira C, Reed JC, Pratt MAC. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
11. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, Dorken B. Overexpression of the death-promoting gene bax-a which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996; 97: 2651-2659.
12. Sumantran VN, Ealogeva MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2507-2510.
13. Meijerink JPP, Mensink EJBM, Wang K, Sedlak TW, Sloetjes AW, de Witte T, Waksman G, Korsmeyer SJ. Hematopoietic malignancies demonstrate loss-of-function mulations of bax. Blood 1998; 91: 2991-2997.
14. Sato T, Irie S, Krajewski S, Reed JC. Cloning and sequencing of cDNA encoding rat bcl-2 protein. Gene 1994; 140: 291-292.
15. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
16. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1851-1854.
17. Blagosklonny M, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 transduction pathway. Cancer Res 1995; 55: 4623-4626.
18. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996; 87: 619-628.
19. Wang H-G, Takayama S, Rapp UR, Reed JC Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci USA 1996; 93: 7063-7068.
20. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994; 91: 5878-5882.
21. Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bcl-2 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996; 16: 3884-3892.
22. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996; 271: 12695-12698.
23. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism tor inhibition of programmed cell death. J Exp Med 1996; 183: 2219-2226.
24. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression. BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 1996; 93: 9545-9552.
25. Huang D, O'Reilly L, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16: 4628-4638.
26. Park JR, Bernstein ID, Hockenberry DM. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood 1995; 86: 868-876.
27. Bradbury DA, Russel NH. Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol 1995; 91: 374-379.
28. Porwit MacDonald A, Ivory K, Wilkinson S, Wheayley K, Wong L, Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 1995; 9: 1191-1196.
29. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
30. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, Hall AG. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 88: 105-109.
31. Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996; 10 (Suppl. 3): S18-S22.
32. Karakas T, Maurer U, Weidmann E, Miething CC. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159-165.
33. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664-1667.
34. Webb A, Cunningham D, Cotter F, Clarke PA, Stefano PA, Ross P, Corbo M, Dziewanowska Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-1141.
35. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT. Modulation of bcl-2 protein levels by an intracellular anti-bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998; 58: 2134-2140.
36. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic separation with MACS. Cytometry 1990; 11: 231-238.
37. Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994; 22: 1003-1010.
38. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M. Minimal residual disease in acute rnyelogenous leukemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematot 1997; 99: 64-75.
39. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, Fong L, Reed JC. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 1994; 54: 5501-5507.
40. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to com-bination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-4478.
41. Kornblau SM, Thall P, Estrov Z, Kantarjian H, Estey E, Andreeff M. Proliferation and apoptosis regulating proteins and cytogenetics predict prognosis in acute myelogenous leukemia. Blood 1997; 90 (Suppl. 1): 308, 71a.
42. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405.
43. Andreeff M, Zhao S, Xie Z, Konopleva M, Estey E, Munsell M, Sanchez-Williams G, Kornblau S, Reed J. Control of apoptosis in AML by Bcl-2 and Bcl-X,: critic impact of cytogenetics. Blood 1998; 92 (Suppl. 1): 3887.
44. Blume-Jensen P, Janknecht R, Hunter T. The kit receptor promotes cell survival via activation of Pl 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 1998; 8: 779-782.
45. Konopleva M, Tari A, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize AML to cytosine-arabinoside, and induce apoptosis independent of other anti-apoptotic proteins. Blood (submitted).
46. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis: molecules and mechanisms. In: Veerman AJP, Pieters R, Kaspers GJL (eds). Drug Resistance in Leukemia and Lymphoma III. Plenum Press: Amsterdam (in press).
47. Konopleva M, Andreeff M. Regulatory pathways in programmed cell death. Cancer Mol Biol 1999; 6: 1229-1260.
48. Estey E, Beran M, Pierce S, Kantarjian H, Keating M. All-traps retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: a randomized study. Blood 1997; 90 (Suppl. 1): 1851, 416a.
49. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retionic acid ± granulocyte-colony stimulating factor in poor prognosis newly-diagnosed non-APL AML and MDS. Blood 1999; 93: 2478-2484.